Agios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
